Matthew Waldbrook

发表

In Vivo, In Vitro, and In Silico Characterization of Peptoids as Antimicrobial Agents

C. Fjell, R. Hancock, A. Barron, 2016, PloS one.

NBI-921352, a first-in-class, NaV1.6 selective, sodium channel inhibitor that prevents seizures in Scn8a gain-of-function mice, and wild-type mice and rats

Angela Hussainkhel, S. Decker, Matthew Waldbrook, 2021, bioRxiv.

Pharmacological determination of the fractional block of Nav channels required to impair neuronal excitability and ex vivo seizures

Matthew Waldbrook, R. R. Parrish, S. Thouta, 2022, bioRxiv.

Potent, Gut-Restricted Inhibitors of Divalent Metal Transporter 1 (DMT1): Preclinical Efficacy Against Iron Overload and Safety Evaluation

I. Tietjen, Y. P. Goldberg, Matthew Waldbrook, 2022, bioRxiv.

Enhanced Leukocyte Recruitment Infections through Chemokine Induction and Provides Protection against Bacterial Synthetic Cationic Peptide IDR-1002

S. Mullaly, H. Jenssen, Matthew Waldbrook, 2010 .

Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs.

Artem Cherkasov, Kai Hilpert, Håvard Jenssen, 2009, ACS chemical biology.

An anti-infective peptide that selectively modulates the innate immune response

Oreola Donini, Robert E W Hancock, B. Finlay, 2007, Nature Biotechnology.

Synthetic Cationic Peptide IDR-1002 Provides Protection against Bacterial Infections through Chemokine Induction and Enhanced Leukocyte Recruitment

R. Hancock, S. Mullaly, H. Jenssen, 2010, The Journal of Immunology.

Selective NaV1.7 Antagonists with Long Residence Time Show Improved Efficacy against Inflammatory and Neuropathic Pain.

D. Sutherlin, D. Hackos, S. Decker, 2018, Cell reports.

Design of Conformationally Constrained Acyl Sulfonamide Isosteres: Identification of N-([1,2,4]Triazolo[4,3- a]pyridin-3-yl)methane-sulfonamides as Potent and Selective hNaV1.7 Inhibitors for the Treatment of Pain.

D. Sutherlin, D. Hackos, A. D. White, 2018, Journal of medicinal chemistry.

Identification of Selective Acyl Sulfonamide-Cycloalkylether Inhibitors of the Voltage-Gated Sodium Channel (NaV) 1.7 with Potent Analgesic Activity.

Benjamin D. Sellers, D. Sutherlin, D. Hackos, 2018, Journal of medicinal chemistry.

Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective NaV1.6 Inhibitors with Efficacy in Mouse Models of Epilepsy.

R. DeVita, S. Decker, Matthew Waldbrook, 2019, Journal of medicinal chemistry.

Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models.

Shifeng Liu, R. Oballa, D. Sutherlin, 2016, ACS medicinal chemistry letters.

Discovery of Acyl-sulfonamide Nav1.7 Inhibitors GDC-0276 and GDC-0310.

D. Sutherlin, Jun Chen, D. Hackos, 2021, Journal of medicinal chemistry.

Ability of Innate Defence Regulator Peptides IDR-1002, IDR-HH2 and IDR-1018 to Protect against Mycobacterium tuberculosis Infections in Animal Models

R. Hancock, R. Hernández-Pando, Matthew Waldbrook, 2013, PloS one.

NaV1.6 inhibition drives the efficacy of voltage-gated sodium channel inhibitors to prevent electrically induced seizures in both wild type and Scn8aN1768D/+ gain-of-function mice

Wei Zhang, Angela Hussainkhel, Matthew Waldbrook, 2023, bioRxiv.

Molecular pharmacology of selective Nav1.6 and dual Nav1.6 and Nav1.2 channel inhibitors that suppress excitatory neuronal activity ex vivo

P. Ruben, Matthew Waldbrook, R. R. Parrish, 2023, bioRxiv.